Nimesulide

Severe: Contraindicated.

Contraindicated.

Should be taken with food.

Hypersensitivity. History of asthma, urticaria or allergic-type reactions after receiving aspirin or other NSAIDs. Active gastrointestinal ulcer, history of gastrointestinal or cerebrovascular bleeding or other bleeding disorders; severe heart failure; alcoholism, substance use disorder; fever or flu-like symptoms, suspected dengue fever. Hepatic and severe renal impairment. Children <12 years. Pregnancy and lactation. Concomitant use with known hepatotoxic agents.

Patient with gastrointestinal disorders (e.g. ulcerative colitis, Crohn's disease, history of peptic ulceration), CV disease, fluid retention, hypertension. Patient taking anticoagulants or platelet aggregation inhibitors. Mild to moderate renal impairment. Elderly.

Significant: Increased risk of gastrointestinal bleeding or ulceration; oedema, anaphylactoid reactions; decreased platelet aggregation, prolonged bleeding time; may cause serious skin reactions (e.g. Stevens-Johnson syndrome).
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, pyrosis, melaena.
Nervous system disorders: Headache, dizziness, drowsiness.
Renal and urinary disorders: Oliguria.
Skin and subcutaneous tissue disorders: Rash, urticaria.
Potentially Fatal: Hepatotoxicity (e.g. liver failure).

Monitor hepatic function (periodically), renal function, CBC and occult blood loss.

May reduce the oral bioavailability of furosemide. May displace fenofibrate, tolbutamide, and salicylic acid from plasma protein binding.

May increase the risk of gastrointestinal bleeding with alcohol.

Description:
Mechanism of Action: Nimesulide is an NSAID that exhibits antipyretic, analgesic and anti-inflammatory properties. It selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, thereby reducing the synthesis of prostaglandins.
Onset: Analgesia: Approx 15 minutes.
Duration: 6-8 hours.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: 1-2 hours.
Distribution: Plasma protein binding: >97.5%.
Metabolism: Extensively metabolised in the liver by CYP2C9; main metabolite is M1 (pharmacologically active).
Excretion: Elimination half-life: 1.8-4.7 hours; 2.9-8.7 hours (M1 metabolite).

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4495, Nimesulide. https://pubchem.ncbi.nlm.nih.gov/compound/Nimesulide. Accessed Sept. 23, 2024.

Store at 25°C.

Thuốc kháng viêm không steroid

M01AX17 - nimesulide ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.

Brayfield A, Cadart C (eds). Nimesulide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/09/2024.

Nidol Tablet (Eurodrug Laboratories). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 19/09/2024.

Nidol Tablet (Eurodrug Laboratories). MIMS Thailand. http://www.mims.com/thailand. Accessed 05/09/2024.

Nimesulide. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 05/09/2024.